Context Therapeutics (NASDAQ:CNTX) Upgraded by Citizens Jmp to Strong-Buy Rating

Citizens Jmp upgraded shares of Context Therapeutics (NASDAQ:CNTX) to a strong-buy rating in a report released on Wednesday,Zacks.com reports.

A number of other brokerages have also commented on CNTX. JMP Securities initiated coverage on Context Therapeutics in a research note on Wednesday. They issued an “outperform” rating and a $4.00 target price for the company. D. Boral Capital began coverage on shares of Context Therapeutics in a report on Monday, November 25th. They set a “buy” rating and a $9.00 price objective for the company. Finally, HC Wainwright reissued a “buy” rating and issued a $6.00 target price on shares of Context Therapeutics in a research note on Monday, September 23rd. Six investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, Context Therapeutics currently has a consensus rating of “Buy” and an average price target of $6.33.

Context Therapeutics Stock Performance

NASDAQ CNTX opened at $1.21 on Wednesday. The stock has a market capitalization of $90.75 million, a PE ratio of -1.33 and a beta of 2.10. The stock has a 50-day simple moving average of $1.52 and a 200 day simple moving average of $1.94. Context Therapeutics has a twelve month low of $0.89 and a twelve month high of $2.75.

Context Therapeutics (NASDAQ:CNTX) last released its earnings results on Wednesday, November 6th. The company reported ($0.22) earnings per share for the quarter, missing the consensus estimate of ($0.11) by ($0.11). As a group, equities research analysts forecast that Context Therapeutics will post -0.51 EPS for the current fiscal year.

Institutional Investors Weigh In On Context Therapeutics

A number of large investors have recently bought and sold shares of the business. Great Point Partners LLC bought a new position in Context Therapeutics in the 2nd quarter valued at $14,876,000. Blue Owl Capital Holdings LP bought a new stake in Context Therapeutics during the 2nd quarter worth about $10,348,000. Driehaus Capital Management LLC acquired a new stake in shares of Context Therapeutics in the second quarter valued at approximately $4,527,000. Nantahala Capital Management LLC bought a new position in Context Therapeutics in the 2nd quarter worth approximately $3,881,000. Finally, Ally Bridge Group NY LLC lifted its holdings in Context Therapeutics by 159.8% during the 2nd quarter. Ally Bridge Group NY LLC now owns 1,886,232 shares of the company’s stock worth $3,782,000 after buying an additional 1,160,281 shares in the last quarter. 14.03% of the stock is currently owned by institutional investors.

About Context Therapeutics

Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.